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Objective: To report a case of typhoid fever contracted in  Portugal in  1994 due to a Salmonella typhi isolate which 
had reduced susceptibility t o  fluoroquinolone (MIC 1 mg/L of ciprofloxacin) and high level resistance to  nalidixic acid 
(MIC 256 mg/L). 
Methods: Molecular studies of reduced susceptibility t o  fluoroquinolones comprised complementation tests with a 
wild-type allele and sequencing directly from PCR products of the gyrA gene. 
Results: Complementation tests and DNA sequencing showed that a mutation occurred in the gyrA gene of this clinical 
isolate, resulting i n  a substitution of phenylalanine for serine at position 83 of GyrA. 
Conclusions: Because quinolones may be regarded as a treatment of choice in typhoid fever, it seems important now 
t o  recommend cautious use of these drugs as first-line therapy and possibly use of nalidixic acid resistance as a marker 
for detection of 'first-step' resistance to  fluoroquinolones in S. typhi. 
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I NTRODU CTI 0 N 
Spread of multiresistant Salmonella typhi has been 
reported frequently over the past few years [l-41, but 
these strains have responded well to fluoroquinolone 
therapy which has become a treatment of choice for 
typhoid fever [S-71. More recently, multiresistant S. 
typhi strains, also resistant to fluoroquinolones, have 
been isolated in Asia (India, Bengladesh, Pakistan, 
Nepal) [8,9]. It has been reported that fluoroquinolone 
resistance in these strains is associated with a mutation 
in the gyrA gene [lo]. We report here a case of typhoid 
fever contracted in Europe (Portugal) and caused by 
a fluoroquinolone resistant strain of S. typhi (strain 
FQ1). 
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CASE REPORT 
An 18-year-old female patient was admitted to our 
institution in early September 1994 with abdominal 
pain and fever. She had been in good health until a 
few days before admission and had no history of recent 
antibiotic treatment. Ten days after a journey to 
northern Portugal, she suffered from headache, nausea 
and giddiness, developed fever (39 "C)  and abdominal 
pain and was hospitalized for further investigation. 
O n  admission, her blood pressure was normal and 
her abdomen was clinically and echographically normal 
(no splenomegaly). The white blood cell count was 
5 . 5 ~  10y/L (72% polymorphs), the hematocrit 37.8%) 
and the platelet count 134x109/L. Liver function 
tests showed moderate cellular damage (serum aspartate 
aminotransferase 72 U/L; alkaline aminotransferase 
53 U/L) while the bilirubin, creatinine and alkaline 
phosphatases were normal. HIV and hepatitis I3 and C 
serologic tests were negative. Blood cultures [6] and 
stool samples grew S. typhi, and the anti-H-agglutinin 
titer was 1/200. 
O n  the day of admission, the patient was given 
amoxicillin (1 g, four times daily, IV), replaced by 
cefiriaxone (4 g once daily, IV) afier isolation of S. typhi. 
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Apyrexia and negative stool culture were obtained after 
5 days; ceftriaxone was replaced by amoxycillin (1 g 




The clinical isolates were identified as S. typhi by 
standard biochemical tests performed on the Api 20E 
system (API bioM&ieux, Marcy-I'Etoile, France) and 
serotyped by slide agglutination using Salmonella anti- 
serum (Diagnostics Pasteur, France). Phage type was 
determined by the French Reference Center for 
Salmonella and Shigella (Institut Pasteur, Paris, France). 
Susceptibility testing 
Antibiotic susceptibility was tested by a disk diffusion 
method on Mueller-Hinton (MH) agar (Diagnostics 
Pasteur, France). Minimal inhibitory concentrations 
(MICs) of fluoroquinolones (pefloxacin, ciprofloxacin 
and nalidixic acid) were determined by an agar plate 
dilution method performed on M H  agar (Diagnostics 
Pasteur, France), with an inoculum of lo4 CFU per 
spot and incubation at 37°C for 18 h. 
Molecular studies of reduced susceptibility to 
fluoroquinolones 
The nucleotide sequences of a section of the gyrA gene 
of the clinical strain (FQ1) and a ciprofloxacin-sensitive 
strain called FQ2 used as a sensitive control were 
determined. 
Chromosomal DNA was prepared as described by 
Sambrook et a1 [ I l l .  
Plasniid DNA was prepared by the alkaline lysis 
method of Birnboim and Doly [12]. This plasmid, 
called pJSWl0l (5.5 kb), is derived from pUC19 by 
ligation at the BamHI and SalI sites of the wild-type 
gyrA gene [ 131. Plasmid DNA was introduced into the 
FQ1 strain by a transformation procedure with CaC12 
[14]. This procedure used competent cells suspended in 
an ice-cold solution of CaC12 (50 mM). After mixing 
200 pL of competent cells and 10-200 ng of DNA 
in a volume of 50 pL, the Eppendorf tubes were 
stored on ice for 30 min and placed in a 42OC water- 
bath for 2min  (heat shock). The cells were then 
diluted in 1 mL of prewarmed (37°C) M H  broth and 
incubated for 60 min at 37OC with gentle agitation. 
A 200-pL volume of the cells was plated and transfor- 
mants were selected on Luria Bertani (LB) agar 
containing ampicillin at 100 pg/mL. 
Chromosomal DNA was prepared from one colony 
of an overnight culture on brain-heart infusion (BHI) 
agar diluted into 1 mL of sterilized water and boiled for 
10 min. A 219-bp fragment from S. typhi was amplified 
by polymerase chain reaction (PCR) using two 
oligonucleotides, 5'-TACTTTACGCCAGA-3' and 
5'-TCCGTATAACGCATTGCC-3', corresponding 
to nucleotides f 3 1  to f 4 5  and f 2 4 0  to 259 for 
forward and reverse reactions, respectively. These 
primers were synthesized with reference to the 
quinolone resistance-determining region (QRDR) of 
S. typhimurium [ 151. Oligonucleotides were synthesized 
by Eurogentec (Angers, France). Reactions were 
performed in a DNA thermal cycler (PHC2, Techne, 
Paris, France): 30 cycles of 1 nlin of denaturation 
at 94"C, 1 min of annealing at 50°C and 1 min of 
extension at 72"C, followed by a final extension step at 
72°C for 5 min. Amplified P C R  fragments isolated 
from 1% agarose gel were purified by using QIA 
quick gel extraction (Qiagen, Hilden, Germany) and 
sequenced with the Promega P C R  Sequencing Kit 
(Promega) according to the manufacturer's recom- 
mendation. 
RESULTS 
AU the isolates were susceptible to ampicillin, cephalo- 
sporins, chloramphenicol, trimethoprim, sulfonamides, 
tetracycline and aminoglycosides. These strains were 
Figure 1 Results of P C R  amplification of a 219-bp 
segment within the quinolone resistance-determining 
region of the resistant (FQ1) and susceptible (FQ2) 
Sulmorzellu typlzi strains: lane a, FQ1; lane b, FQ2; 
lane c, P C R  in which no DNA was added (negative 
control); lane d, molecular weight marker (Kaoul 
Appligene, Illkirch, France). 
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resistant to nalidixic acid and had reduced susceptibility 
to fluoroquinolones. The MIC of nalidixic acid was 
2 2 5 6  mg/L and the MICs of pefloxacin and cipro- 
floxacin were 2 and 1 mg/L, respectively. 
An isolate of S. typhi from blood culture, referred 
to as FQ1 of lysotype A, was used for further studies. 
Transformation of S. typhi F Q l  with plasmid 
carrying the wild-type gyrA gene resulted in restoration 
of susceptibility to nalidixic acid, pefloxacin and cipro- 
floxacin, with MICs, respectively, of 1, 0.06 and 0.007 
pg/mL indicating that S. typlzi FQ1 had a mutation 
in gyrA. 
PCK products (as illustrated in Figure 1) from the 
ciprofloxacin-resistant isolate FQ1 from the patient 
and the ciprofloxacin-sensitive strain FQ2, produced as 
described above, were sequenced and found to show 
two mutations: a C+T transition at the position 
equivalent to nucleotide 248 of gyrA,  resulting in a 
Ser83-+Phe substitution; and a silent mutation at the 
position equivalent to nucleotide 354 (A+C). 
DISCUSSION 
Typhoid fever is a serious infection, still observed in 
many countries. Treatment by fluoroquinolones has 
been shown to be effective and well tolerated in many 
clinical trials [7]. Fluoroquinolones represent a treat- 
ment of choice, because many S. typhi isolates are 
multiply resistant to several unrelated drugs, including 
ampicillin, chloramphenicol and trimethoprim 171. 
Additionally, fluoroquinolones have been successfully 
used for the eradication of long-term gastrointestinal 
carriage 171. 
Kecent reports, however, have shown that some 
multiresistant isolates do not respond to fluoroquino- 
lone therapy 116-181. Many of these strains had 
reduced susceptibility to fluoroquinolones (MIC of 
ciprofloxacin 0.25 pg/mL). A mutation at serine-83 in 
the GyrA protein has been shown in several strains to 
confer decreased susceptibility to fluoroquinolones. In 
most but not all strains, high-level resistance to nalidixic 
acid was observed, and it has been reported that some 
of these S. typlzi isolates did not respond to cipro- 
floxacin therapy 
More recently, two strains of S. typhi less susceptible 
to fluoroquinolones, acquired in western Europe, 
have been isolated. The first strain was described by 
Le Lostec et a1 [19] and the second is described in 
this paper (strain FQ1). Both strains were isolated from 
patients with a history of recent travel in northern 
Portugal. Both strains, unlike the Asian strains, were 
susceptible to ampicillin, chloramphenicol and tri- 
methoprini. MICs of ciprofloxacin were 0.12 and 
1 pg/nlL, respectively, and both belonged to lysotype 
A. Initial treatment of the first patient with fluoro- 
quinolone was ineffective, with fever and positive blood 
culture persisting after 48 h; this patient was successfully 
treated with amoxycillin. Our  patient was initially 
given anioxycillin, and then ceftriaxone, but no fluoro- 
quinolone was used. Complementation tests with a 
wild-type allele of strain FQ1 showed that a mutation 
had occurred in the gyrA gene of this clinical isolate, 
with a serine to phenylalanine substitution at position 
83, similar to that described in Asian strains [lo]. 
Problems arising from S. typhi strains with reduced 
susceptibility to fluoroquinolones must be kept in mind 
by clinicians and microbiologists, since failures of treat- 
ment with ciprofloxacin have been reported [16-19] 
Furthermore, the number of such strains with low-level 
resistance to fluoroquinolones is underestimated, since, 
in the usual susceptibility tests with the breakpoints 
presently accepted worldwide, such strains are cate- 
gorized as susceptible. Therefore to detect this low level 
of resistance, we would suggest that all S. typhi isolates 
should be tested with nalidixic acid 30 pg disk as well 
as with ciprofloxacin. Strains resistant to nalidixic acid 
should be reported to the clinician, and the MIC of 
ciprofloxacin measured. 
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